Secukinumab for treating moderate to severe plaque psoriasis in children and young people

Equality Impact Assessment (Guidance development) (PDF 144 KB)

Final draft guidance: 1

Committee papers and slides (PDF 2.43 MB)

Final appraisal document (PDF 183 KB)

Final scope (PDF 195 KB)

Final stakeholder list (PDF 182 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 331 KB)

Equality impact assessment (Scoping) (PDF 126 KB)

Draft scope pre referral (PDF 210 KB)

Draft matrix pre referral (PDF 182 KB)